Interim Results for the six months ended 31 October 2025

About this update from Scancell Holdings Plc

OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a business update and provides its unaudited financial results for the six-month period to 31 October 2025. Highlights (including post period) DNA ImmunoBody ® iSCIB1+ (SCOPE trial): Moditope® Modi-1 (ModiFY trial): Antibodies: Financial: Outlook Key near-term milestones include: Phil L'Huillier, Chief Executive Officer, Scancell, commented: "iSCIB1+ has demonstrated strong potential to redefine standard of care for advanced melanoma, and we are proud to advance this new off-the-shelf treatment for cancer patients through clinical development to address what remains a significant unmet medical need. Based on the strong Phase 2 SCOPE data, we accelerated our plans for a global registrational Phase 3 study and have now received a rapid clearance for our IND from the US FDA as well as positive feedback from other regulators including EMA and MHRA. We are well positioned to initiate the study in 2026. We continue our partnering discussions on iSCIB1+ and the ImmunoBody® platform with the regulatory feedback in hand and will evaluate all financing options with the dual focus on progressing the Phase 3 trial in a timely manner and optimising shareholder value. There is continuing partnering interest in our lead antibody, SC134, and our other GlyMab® candidates through which we expect to generate further shareholder value in the coming year, while we will also explore partnering opportunities for Moditope® following new Modi-1 Phase 2 data expected in H1 2026." Phil L'Huillier, Chief Executive Officer and Sath Nirmalananthan, Chief Financial Officer, will also host a live webcast for analysts and investors today at 14:00 GMT. If you would like to join the webcast, please follow this link: Interim Financial Results for the six months ending 31 October 2025 | SparkLive | LSEG A replay of the webcast will be made available shortly afterwards. A full copy of the announcement can be found on the Scancell website: www.scancell.co.uk This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR). About Scancell Scancell (LSE:SCLP; www.scancell.co.uk) is a cl...

View stock analysis, news, and events for Scancell Holdings Plc